Incorporating Digital Rectal Examination (DRE) alongside Prostate-Specific Antigen (PSA) screening has been shown to offer significant economic benefits, owing to its heightened sensitivity, specificity, and diagnostic accuracy in detecting prostate cancer [21]. The gene discussed is KLK3; the disease is prostate carcinoma.